Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma

PURPOSE: Copy number alterations have been shown to be involved in melanoma pathogenesis. The randomized, phase III clinical trial E2603: carboplatin, paclitaxel, +/− sorafenib (CP vs. CPS) offers a large collection of tumor samples to evaluate association of somatic mutations, genomic alterations,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Wilson, Melissa A., Zhao, Fengmin, Khare, Sanika, Roszik, Jason, Woodman, Scott E., D'Andrea, Kurt, Wubbenhorst, Bradley, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Schuchter, Lynn M., Lee, Sandra J., Flaherty, Keith T., Nathanson, Katherine L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4821426/
https://ncbi.nlm.nih.gov/pubmed/26307133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1162
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk